New hope for tough ovarian cancer: drug SHR-A1811 takes on chemo in major trial

NCT ID NCT06828354

First seen May 13, 2026 · Last updated May 15, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a new drug called SHR-A1811 works better than standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 300 participants will be randomly assigned to receive either SHR-A1811 or a chemotherapy chosen by their doctor. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, Shandong, 250012, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.